Oncology / Haematology

2019/02/14MEDICAL UPDATE

Highlights from ASH 2018

by Esther Drain As usual, ASH provided lots of exciting updates in the management of lymphoma. One particularly interesting study from which data was presented at ASH was the ECHELON-2 study, which compared BV+CHP vs CHOP for patients with peripheral T-cell lymphoma. In the video above, Dr Graham Collins (Oxford, UK), Dr Alison J. Moskowitz (New York, USA) and Professor Andrei Shustov (Seattle, USA) provide their highlights from the meeting.

READ MORE

2019/02/05MEDICAL UPDATE

ASH 2018: Hodgkin lymphoma: beyond ABVD for everyone

By Tom Collins (author) and Hannah Chatfield (interviews) Achieving the ultimate goals of maintaining cure and minimising long-term toxicity in Hodgkin lymphoma (HL) requires individualised therapy based on risk stratification of patients...

READ MORE

2019/02/05MEDICAL UPDATE

ASH 2018: Advances in the management of peripheral T-cell lymphoma

By Maria Dalby (article) and Esther Drain (interviews) Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of lymphoid malignancies that often fails to respond to standard of care treatment,1-3 and the need for new therapies is therefore urgent...

READ MORE

2019/02/05MEDICAL UPDATE

ASH 2018: Follicular Lymphoma: Have We Made Progress?

by Tom Collins (author) and Hannah Chatfield (interview) Follicular lymphoma (FL) is the most common form of indolent non-Hodgkin lymphomas1 and although rarely curable, a number of treatment options exist. In an education session on current and emerging options for the treatment of FL, respectively, presentations focused on data supporting rituximab as single-agent or in combination with chemotherapy and as maintenance therapy in newly-diagnosed FL, and chemotherapy-free regimens and novel immunotherapy approaches in relapsed FL...

READ MORE

2019/02/01MEDICAL UPDATE

ASH 2018: Integrating CAR T-Cell Therapy Into the Treatment of Lymphoma

by Tom Collins (article) and Hannah Chatfield (interview) The use of CAR T-cell therapy in lymphomas represents a very novel and fast-moving area of research with continuous preclinical and clinical advances...

READ MORE

2019/01/14MEDICAL UPDATE

ASH 2018: Treating CTCL in the real-world

Dr Horwitz discusses treating CTCL in the real-world. 

READ MORE

2018/08/20MEDICAL UPDATE

ASCO 2018: Hot topics in lung cancer

Hot topics in lung cancer - interviews from ASCO 2018.

READ MORE

2018/06/24MEDICAL UPDATE

EHA 2018: OPTIMISMM

(Author: Maria Dalby; Interviewer: Esther Drain) Professor Paul Richardson (Boston, USA) presented the results of the OPTIMISMM study which compared the efficacy of pomalidomide, bortezomib and dexamethasone (PVd) with bortezombib and dexamethasone alone (Vd) in MM patients with 1-3 prior lines of therapy and a minimum of two cycles of lenalidomide treatment.

READ MORE

2018/06/24MEDICAL UPDATE

EHA 2018: Immunotherapy in MM: why, when and how?

(Author: Maria Dalby; Interviewer: Esther Drain) The pathophysiology of MM is characterised by a state of profound immunosuppression through multiple mechanisms which provides a strong rationale for immunotherapeutic approaches including antibodies, immunomodulators, vaccines and adoptive cellular therapies. In an educational session at EHA 2018 Dr Niels van de Donk from Amsterdam outlined the importance of immunotherapy in the treatment of MM now and in the future, focussing especially the role of antibody combinations in the upfront setting and the promise of CAR-T cell therapy.

READ MORE

2018/06/24MEDICAL UPDATE

EHA 2018: The Issue of Frailty in MM

(Author: Maria Dalby; Interviewer: Esther Drain) When treating patients with MM frail patients are less able to tolerate aggressive treatment and therefore have poorer OS. In the era of novel agents there is a medical need for maximising tolerability and optimising efficacy in elderly patients by individualising therapy based on fitness rather than chronological age. Professor Sonja Zweegman from Amsterdam hosted a Meet the Expert session at EHA 2018 which highlighted some of the challenges around detecting and assessing frailty and adapting therapy so that frail patients can achieve the best possible outcome.

READ MORE